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Background
• Current anti-TB administration strategies are based on long-term oral dosing 
• Oral administration is characterised by suboptimal adherence which 
represents a leading cause of treatment failure
• 20 to 50% of patients fail to complete existing tuberculosis treatment 
• Injectable long-acting nano-formulations have been applied in numerous 
disease areas to simplify drug administration
• Long-acting administration of anti-TB agents could represent a valuable 
pharmacological strategy
Cuneo WD, Snider DE Jr. Clin Chest Med. 1989 Sep;10(3):375-80.
Munro SA et al. PLoS Med. 2007; 4(7): e238.
Aims
• Design and validate a physiologically based pharmacokinetic (PBPK) model 
for existing oral anti-TB agents
• Simulate the pharmacokinetics of long-acting formulations of anti-TB agents 
in adult individuals
PBPK model
• Physiologically based pharmacokinetic (PBPK) modelling was used to inform 
the pharmacokinetics of anti-TB agents in adults
 Mathematical description of absorption, distribution, metabolism and 
elimination processes defining pharmacokinetics 
 PBPK modelling integrates in vitro and clinical data to simulate drug 
distribution in virtual population 
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Study design
Validation
Prediction
• Existing available oral anti-TB formulations of bedaquiline, delamanid
and rifapentine were validated in adults
• Mean simulated values from 100 virtual individuals (aged 18-60 years) 
were compared with available clinical data
• Virtual IM depot was included in the model to simulate IM 
administration  
• Maximum feasible human IM dose of 2000 mg was assumed for 
pharmacokinetic predictions in the current study
• Release rate was selected in order to obtain maximal exposure over 
the dosing interval
Validation against clinical formulations
Clinical Simulated
Drug Cmax (µg/ml) Cmin (µg/ml) AUC (µg.h/ml) Cmax (µg/ml) Cmin (µg/ml) AUC (µg.h/ml)
Bedaquiline
(450 mg OD, single dose)1
3.76 ± 1.17 - ‡64.5 ± 26.9 3.59 ± 0.79 - ‡63.1 ± 15.6
Delamanid
(300 mg OD, day 10)2
0.41 ± 0.05 0.14 ± 0.04 †5.84 ± 0.99 0.45 ± 0.13 0.13 ± 0.08 †6.57 ± 2.31
Rifapentine
(10 mg/kg OD, day 14)3
21.7 (21.3-22.2) - †330 (284-340) 18.9 ± 2.4 8.6 ± 1.5 †327 ± 44
†AUC0-24, 
‡AUC0-144
1van Heeswijk RP, Dannemann B, Hoetelmans RM., J Antimicrob Chemother. 2014 Sep;69(9):2310-8.
2Deltyba, Assessment report, EMA, 2014.
3Dooley KE et al. Clin Pharmacol Ther. 2012 May ; 91(5).
Release rate optimisation
Release rate – 0.04 h-1
Release rate – 0.004 h-1
Release rate – 0.0004 h-1
Therapeutic cut-off
representative
Drug
AUC
(Mean ± SD)
(µg.h/ml)
Cmax
(Mean ± SD)
(µg/ml)
Ctrough
(Mean ± SD)
(µg/ml)
Cut-off limit
(µg/ml)
Bedaquiline 271 ± 65 0.72 ± 0.16 0.14 ± 0.04 1.6 (ECOFF)
Delamanid 89 ± 16 0.23 ± 0.04 0.05 ± 0.01 0.04 (ECOFF)
Rifapentine 1639 ± 160 4.12 ± 0.38 0.88 ± 0.09 0.06 (MIC)
Prediction - Summary
IM Dose – 2000 mg/30 days IM release rate – 0.0025 h-1
Limitations
• Activity of transporters can affect distribution and elimination patterns
• Drugs with high lipophilicity tend to diffuse through the lymphatic 
circulation rather than through blood
• The technological complexities associated with reformulation may 
constitute a barrier for some anti-TB agents
• Long term stability of anti-TB agents in potential long-acting formulations is 
unknown 
Conclusion
• This theoretical approach could assist in informing the design of long-acting formulation 
for IM administration of anti-TB agents
• PBPK modelling represents a predictive tool to rationalise anti-TB agent 
pharmacokinetics and hypothesise potential applications of long-acting anti-TB therapy
• Lack of clear pharmacodynamics cut-offs and clinical validation of alternative 
combinations complicates the selection of suitable long-acting candidates
• Long-acting formulations could also find potential application in the treatment of latent 
TB or chemoprophylaxis
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